Open AccessBevacizumab is more effective in nasopharyngeal carcinoma patients with lower maximum radiation dose to the temporal lobe
Author(s) -
Adam A. Garsa,
Jennifer Ho,
Chaosu Hu,
Eric L. Chang
Publication year - 2019
Publication title -
chinese clinical oncology
Language(s) - English
Resource type - Journals
eISSN - 2304-3873
pISSN - 2304-3865
DOI - 10.21037/cco.2019.02.06
Subject(s) - nasopharyngeal carcinoma , medicine , radiation therapy , temporal lobe , skull , radiation dose , bevacizumab , radiology , carcinoma , nuclear medicine , pathology , surgery , chemotherapy , psychiatry , epilepsy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom